These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 366325)

  • 21. [Comparative study of fluorescent antibody indirect reactions in Chagas' disease, mucocutaneous leishmaniasis and kala-azar using various Leishmania and Trypanosoma antigens].
    Nery-Guimarães F; Lage HA; Venancio IA; Grynberg NF
    Hospital (Rio J); 1969 May; 75(5):1811-25. PubMed ID: 4979318
    [No Abstract]   [Full Text] [Related]  

  • 22. Apparent Glucantime failure in five patients with mucocutaneous leishmaniasis.
    Rocha RA; Sampaio RN; Guerra M; Magalhâes A; Cuba CC; Barreto AC; Marsden PD
    J Trop Med Hyg; 1980 Aug; 83(4):131-9. PubMed ID: 6997505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronic nasofacial ulceration disclosing muco-cutaneous leishmaniasis].
    Farge D; Wechsler B; Frances C; Vouldoukis I; Monjour L; Negrier B; Gentilini M; Freyss G; Godeau P
    Ann Med Interne (Paris); 1987; 138(5):380-2. PubMed ID: 3674617
    [No Abstract]   [Full Text] [Related]  

  • 24. [Diagnosis and treatment of kala-azar].
    Neves J
    Rev Paul Med; 1983; 101(6):237-9. PubMed ID: 6677985
    [No Abstract]   [Full Text] [Related]  

  • 25. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.
    Antinori S; Longhi E; Bestetti G; Piolini R; Acquaviva V; Foschi A; Trovati S; Parravicini C; Corbellino M; Meroni L
    Br J Dermatol; 2007 Nov; 157(5):1032-6. PubMed ID: 17854365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review.
    Hernández-Pérez J; Yebra-Bango M; Jiménez-Martínez E; Sanz-Moreno C; Cuervas-Mons V; Alonso Pulpón L; Ramos-Martínez A; Fernández-Fernández J
    Clin Infect Dis; 1999 Oct; 29(4):918-21. PubMed ID: 10589910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions.
    Couppié P; Clyti E; Sainte-Marie D; Dedet JP; Carme B; Pradinaud R
    Am J Trop Med Hyg; 2004 Nov; 71(5):558-60. PubMed ID: 15569784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Transitory deficiency of factor VII in a case of kala-azar].
    Pagano L; Marra R; De Stefano V; Storti S; Leone G
    Recenti Prog Med; 1988 Sep; 79(9):377-8. PubMed ID: 3201035
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cutaneous and muucocutaneous leishmaniasis. New findings on the subject].
    Sangüeza P; Cardenas F
    Med Cutan Ibero Lat Am; 1981; 9(1):25-34. PubMed ID: 7022056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of kala-azar in India.
    Thakur CP
    Natl Med J India; 1992; 5(5):203-5. PubMed ID: 1338871
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Borderline cutaneous leishmaniasis. Clinical, immunological and histological differences from mucocutaneous leishmaniasis.
    Moriearty PL; Bittencourt AL; Pereira C; Teixeira R; Barreto E; Guimarães NA
    Rev Inst Med Trop Sao Paulo; 1978; 20(1):15-21. PubMed ID: 418492
    [No Abstract]   [Full Text] [Related]  

  • 33. [Autochtonous kala-azar (author's transl)].
    Castel Y; Chastel C; Le Moigne C; Simitzis AM; Le Fur JM
    Arch Fr Pediatr; 1982 Feb; 39(2):97-8. PubMed ID: 7073440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mucocutaneous Leishmaniasis: an imported illness with ENT repercussions].
    González M; Benito F; García L; Iglesias A
    Acta Otorrinolaringol Esp; 2009; 60(4):298-300. PubMed ID: 19814979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cutaneous leishmaniasis in Algeria (author's transl)].
    Bobin P; Barabe P; Bordahandy R; Calzolari M; Dedet JP
    Med Trop (Mars); 1978; 38(4):419-24. PubMed ID: 732557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell mediated immunity in American cutaneous and mucosal leishmaniasis.
    Carvalho EM; Johnson WD; Barreto E; Marsden PD; Costa JL; Reed S; Rocha H
    J Immunol; 1985 Dec; 135(6):4144-8. PubMed ID: 4067312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Leishmaniasis in Greece. Results of an entomological survey during June 1977 (author's transl)].
    Leger N; Saratsiotis A; Pesson B; Leger P
    Ann Parasitol Hum Comp; 1979; 54(1):11-29. PubMed ID: 485036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnosis and differential diagnosis of cutaneous leishmaniasis. Report on seven cases observed in Zurich].
    Schwarz KJ
    Schweiz Med Wochenschr; 1970 Nov; 100(48):2073-8. PubMed ID: 5524728
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.